Serum long noncoding RNA H19/micro RNA-675-5p axis as a probable diagnostic biomarker in inflammatory bowel disease.
H19
Inflammatory bowel disease
LncRNA
miRNA-675
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
23
07
2023
accepted:
22
08
2023
medline:
10
11
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
A significant body of research strengthens the starring role of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the pathogenesis of inflammatory bowel disease (IBD). Here, we investigated the diagnostic utility of lncRNA H19 and miRNA-675-5p in IBD. This study included 97 participants, thirty-five ulcerative colitis patients, thirty-two Crohn's disease patients, and thirty IBD-free controls. History, staging, laboratory investigations, and colonoscopy were performed. Also, quantitative real-time PCR (qPCR) for revealing of lncRNA H19 and miRNA-675-5p was done. The estimated serum levels for H19 and miRNA-675-5p in the UC and CD groups in comparison to the control group showed a high statistical difference (P = 0.0001 for each parameter). Based upon the severity of UC patients, both biomarkers showed significantly higher values between remission and moderate cases, with p-values 0.022 and 0.02, respectively. Meanwhile, in CD patients, both biomarkers revealed no statistical significance between remission and any active stage of the disease. Additionally, ROC analysis revealed that H19 could discriminate between UC and control subjects with 94.3% sensitivity and 90.0% specificity, and with 87.5% sensitivity, and 88.5% specificity in the CD group. Furthermore, miR-675-5p was able to discriminate between UC and control subjects with 85.7% sensitivity and 97.3% specificity and with 88.4% sensitivity, 95.2% specificity in the CD group. Logistic regression found a significant predictive utility of using miR-675-5p and H19 in IBD. H19 and miRNA-675-5p can be used as diagnostic biomarkers in IBD, with superiority in UC patients with moderate activity.
Sections du résumé
BACKGROUND
BACKGROUND
A significant body of research strengthens the starring role of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) in the pathogenesis of inflammatory bowel disease (IBD). Here, we investigated the diagnostic utility of lncRNA H19 and miRNA-675-5p in IBD.
METHODS
METHODS
This study included 97 participants, thirty-five ulcerative colitis patients, thirty-two Crohn's disease patients, and thirty IBD-free controls. History, staging, laboratory investigations, and colonoscopy were performed. Also, quantitative real-time PCR (qPCR) for revealing of lncRNA H19 and miRNA-675-5p was done.
RESULTS
RESULTS
The estimated serum levels for H19 and miRNA-675-5p in the UC and CD groups in comparison to the control group showed a high statistical difference (P = 0.0001 for each parameter). Based upon the severity of UC patients, both biomarkers showed significantly higher values between remission and moderate cases, with p-values 0.022 and 0.02, respectively. Meanwhile, in CD patients, both biomarkers revealed no statistical significance between remission and any active stage of the disease. Additionally, ROC analysis revealed that H19 could discriminate between UC and control subjects with 94.3% sensitivity and 90.0% specificity, and with 87.5% sensitivity, and 88.5% specificity in the CD group. Furthermore, miR-675-5p was able to discriminate between UC and control subjects with 85.7% sensitivity and 97.3% specificity and with 88.4% sensitivity, 95.2% specificity in the CD group. Logistic regression found a significant predictive utility of using miR-675-5p and H19 in IBD.
CONCLUSION
CONCLUSIONS
H19 and miRNA-675-5p can be used as diagnostic biomarkers in IBD, with superiority in UC patients with moderate activity.
Identifiants
pubmed: 37716920
doi: 10.1007/s11033-023-08777-8
pii: 10.1007/s11033-023-08777-8
pmc: PMC10635930
doi:
Substances chimiques
RNA, Long Noncoding
0
MicroRNAs
0
Biomarkers
0
MIRN675 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9029-9036Informations de copyright
© 2023. The Author(s).
Références
Cell Res. 2023 May;33(5):372-388
pubmed: 37055591
Dig Dis. 2021;39(3):190-203
pubmed: 32942275
Int J Biol Sci. 2021 Jul 25;17(12):3188-3208
pubmed: 34421359
Int J Oncol. 2015 May;46(5):2241-50
pubmed: 25707431
J Med Life. 2021 May-Jun;14(3):310-315
pubmed: 34377195
World J Gastroenterol. 2021 May 28;27(20):2521-2530
pubmed: 34092973
Scand J Gastroenterol. 2015 Mar;50(3):300-5
pubmed: 25535653
Inflamm Bowel Dis. 2016 Nov;22(11):2582-2592
pubmed: 27661667
Exp Mol Med. 2018 Dec 6;50(12):1-14
pubmed: 30523244
Cell Physiol Biochem. 2017;44(2):581-593
pubmed: 29145193
Mol Cell Biol. 2016 Apr 15;36(9):1332-41
pubmed: 26884465
Cell Death Dis. 2020 Jun 15;11(6):456
pubmed: 32541691
Int J Mol Sci. 2023 Jan 12;24(2):
pubmed: 36675038
Clin Gastroenterol Hepatol. 2016 Mar;14(3):348-354.e17
pubmed: 26071941
Gastroenterology. 2022 Apr;162(4):1147-1159.e4
pubmed: 34995526
Cell Mol Gastroenterol Hepatol. 2020;9(4):611-625
pubmed: 31862317
Oncotarget. 2015 Oct 13;6(31):31958-84
pubmed: 26376677
Int J Mol Sci. 2022 Aug 06;23(15):
pubmed: 35955886
J Med Biochem. 2023 Aug 25;42(3):420-426
pubmed: 37814617
Inflamm Bowel Dis. 2023 Jun 1;29(6):986-999
pubmed: 36545755
Oncol Res. 2016;23(3):99-107
pubmed: 26931432
Int Arch Allergy Immunol. 2022;183(9):985-996
pubmed: 35483327
Ann Transl Med. 2019 Sep;7(18):494
pubmed: 31700930
Front Immunol. 2022 Jun 06;13:865777
pubmed: 35734163
J Exp Clin Cancer Res. 2020 Jul 22;39(1):141
pubmed: 32698890
Gastroenterology. 2021 Jan;160(2):524-537
pubmed: 33253681
Gastroenterology. 2018 Jul;155(1):144-155
pubmed: 29621481
Biomed Pharmacother. 2020 Mar;123:109774
pubmed: 31855739
PLoS One. 2014 Jan 23;9(1):e86295
pubmed: 24466011
PLoS One. 2014 Dec 29;9(12):e116117
pubmed: 25546151
Mayo Clin Proc. 2019 Jan;94(1):155-165
pubmed: 30611442